A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Moban Side Effects, and Drug Interactions - Molindone
Moban Side Effects, and Drug Interactions - Molindone
SIDE EFFECTS
CNS EFFECTS
The most frequently occurring effect is initial drowsiness that generally subsides
with continued usage of the drug or lowering of the dose.
Noted less frequently were depression, hyperactivity and euphoria.
Neurological
Extrapyramidal REACTIONS
Extrapyramidal reactions noted below may occur in susceptible individuals and
are usually reversible with appropriate management.
Akathisia
Motor restlessness may occur early.
Parkinson Syndrome
Akinesia, characterized by rigidity, immobility and reduction of voluntary
movements and tremor, have been observed. Occurrence is less frequent than akathisia.
Dystonic Syndrome
Prolonged abnormal contractions of muscle groups occur infrequently. These
symptoms may be managed by the addition of a synthetic antiparkinson agent (other
than L-dopa), small doses of sedative drugs, and/or reduction in dosage.
Tardive Dyskinesia
Neuroleptic drugs are known to cause a syndrome of dyskinetic movements commonly
referred to as tardive dyskinesia. The movements may appear during treatment
or upon withdrawal of treatment and may be either reversible or irreversible
(i.e., persistent) upon cessation of further neuroleptic administration.
The syndrome is known to have a variable latency for development and the duration
of the latency cannot be determined reliably. It is thus wise to assume that
any neuroleptic agent has the capacity to induce the syndrome and act accordingly
until sufficient data has been collected to settle the issue definitively for
a specific drug product. In the case of neuroleptics known to produce the irreversible
syndrome, the following has been observed.
Tardive dyskinesia has appeared in some patients on long-term therapy and has
also appeared after drug therapy has been discontinued. The risk appears to
be greater in elderly patients on high-dose therapy, especially females. The
symptoms are persistent and in some patients appear to be irreversible. The
syndrome is characterized by rhythmical involuntary movements of the tongue,
face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering
of mouth, chewing movements). There may be involuntary movements of extremities.
There is no known effective treatment of tardive dyskinesia; antiparkinsonism
agents usually do not alleviate the symptoms of this syndrome. It is suggested
that all antipsychotic agents be discontinued if these symptoms appear. Should
it be necessary to reinstitute treatment, or increase the dosage of the agent,
or switch to a different antipsychotic agent, the syndrome may be masked. It
has been reported that fine vermicular movements of the tongue may be an early
sign of the syndrome and if the medication is stopped at that time the syndrome
may not develop (See WARNINGS).
Autonomic Nervous System
Occasionally blurring of vision, tachycardia, nausea, dry mouth and salivation
have been reported. Urinary retention and constipation may occur particularly
if anticholinergic drugs are used to treat extrapyramidal symptoms. One patient
being treated with MOBAN (molindone hydrochloride) experienced priapism which
required surgical intervention, apparently resulting in residual impairment
of erectile function.
Laboratory Tests
There have been rare reports of leucopenia and leucocytosis. If such reactions
occur, treatment with MOBAN may continue if clinical symptoms are absent. Alterations
of blood glucose, B.U.N., and red blood cells have not been considered clinically
significant.
Metabolic and Endocrine Effects
Alteration of thyroid function has not been significant. Amenorrhea has been
reported infrequently. Resumption of menses in previously amenorrheic women
has been reported. Initially heavy menses may occur. Galactorrhea and gynecomastia
have been reported infrequently. Increase in libido has been noted in some patients.
Impotence has not been reported. Although both weight gain and weight loss have
been in the direction of normal or ideal weight, excessive weight gain has not
occurred with MOBAN.
Hepatic Effects
There have been rare reports of clinically significant alterations in liver
function in association with MOBAN use.
Cardiovascular
Rare, transient, non-specific T wave changes have been reported on E.K.G. Association
with a clinical syndrome has not been established. Rarely has significant hypotension
been reported.
Ophthalmological
Lens opacities and pigmentary retinopathy have not been reported where patients
have received MOBAN. In some patients, phenothiazine induced lenticular opacities
have resolved following discontinuation of the phenothiazine while continuing
therapy with MOBAN.
Skin
Early, non-specific skin rash, probably of allergic origin, has occasionally
been reported. Skin pigmentation has not been seen with MOBAN usage alone.
MOBAN has certain pharmacological similarities to other antipsychotic agents.
Because adverse reactions are often extensions of the pharmacological activity
of a drug, all of the known pharmacological effects associated with other antipsychotic
drugs should be kept in mind when MOBAN is used. Upon abrupt withdrawal after
prolonged high dosage an abstinence syndrome has not been noted.
DRUG INTERACTIONS
Potentiation of drugs administered concurrently with MOBAN has not been reported.
Additionally, animal studies have not shown increased toxicity when MOBAN is
given concurrently with representative members of three classes of drugs (i.e.,
barbiturates, chloral hydrate and antiparkinson drugs).
top
